



# NORRIS

## MEDICINES LIMITED



**Factory** : Plot No. 801/P, 901/3-5, GIDC Estate, ANKLESHWAR 393 002. (Gujarat)  
**Regd. Office** : Plot No. 801/P, GIDC Estate, ANKLESHWAR 393 002. (Gujarat)  
**Telephone** : (02646) 223462, 227530  
**Fax** : (02646) 250126  
**E-mail** : contact@norrispharma.com  
**Website** : www.norrispharma.com  
**CIN** : L24230MH1990PLC058071

**New CIN : L24230GJ1990PLC086581**

**STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER & HALF YEAR ENDED 30TH SEPTEMBER, 2016**

(Rs. In Lacs)


Sr. No.	Particulars	Quarter Ended (Unaudited)			Half Year Ended (Unaudited)		Year Ended (Audited)
		30.09.2016	30.06.2016	30.09.2015	30.09.2016	30.09.2015	31.03.2016
<b>1</b>	<b>Income from Operations</b>						
	(a) Net Sales/Income from Operations	664.17	417.78	558.68	1081.95	925.82	1885.63
	(b) Other Operating Income	0.00	0.11	0.00	0.11	0.00	29.68
	<b>Total Income From Operations ( Net)</b>	<b>664.17</b>	<b>417.89</b>	<b>558.68</b>	<b>1082.06</b>	<b>925.82</b>	<b>1915.31</b>
<b>2</b>	<b>Expenses</b>						
	a. Cost of Materials Consumed	349.69	192.29	272.55	541.98	475.34	959.36
	b. Purchase of Stock in Trade	0.00	0.00	0.00	0.00	0.00	0.00
	c. Changes in Inventories of Finished Goods, work in Progress and stock in trade	35.57	7.67	5.90	43.24	-42.93	-29.39
	d. Employee Benefit Expenses	139.74	116.49	127.10	256.23	227.66	483.53
	e. Depreciation and Amortisation Expense	14.50	14.50	31.47	29.00	62.94	59.81
	f. Loss/Gain on Foreign Exchange Transactions	0.00	0.00	-0.05	0.00	-0.50	0.00
	g. Other expenditure	116.70	97.48	93.62	214.18	184.68	388.69
	<b>Total Expenses</b>	<b>656.20</b>	<b>428.43</b>	<b>530.59</b>	<b>1084.63</b>	<b>907.19</b>	<b>1862.00</b>
<b>3</b>	<b>Profit/ (Loss) from operations before Other Income, Finance Costs and exceptional items (1-2)</b>	<b>7.97</b>	<b>-10.54</b>	<b>28.09</b>	<b>-2.57</b>	<b>18.63</b>	<b>53.31</b>
<b>4</b>	<b>Other Income</b>	<b>0.18</b>	<b>0.07</b>	<b>1.94</b>	<b>0.25</b>	<b>6.05</b>	<b>0.00</b>
<b>5</b>	<b>Profit/ (Loss) from Ordinary activities before Finance Costs and Exceptional Items (3+4)</b>	<b>8.15</b>	<b>-10.47</b>	<b>30.03</b>	<b>-2.32</b>	<b>24.68</b>	<b>53.31</b>
<b>6</b>	<b>Finance Costs</b>	<b>12.73</b>	<b>12.15</b>	<b>15.83</b>	<b>24.88</b>	<b>28.99</b>	<b>67.03</b>
<b>7</b>	<b>Profit/ (Loss) from Ordinary activities after Finance Costs but before Exceptional Items (5-6)</b>	<b>-4.58</b>	<b>-22.62</b>	<b>14.20</b>	<b>-27.20</b>	<b>-4.31</b>	<b>-13.72</b>
<b>8</b>	<b>Exceptional Items</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
<b>9</b>	<b>Profit/ (Loss) from Ordinary activities before Tax</b>	<b>-4.58</b>	<b>-22.62</b>	<b>14.20</b>	<b>-27.20</b>	<b>-4.31</b>	<b>-13.72</b>
<b>10</b>	<b>Tax Expense</b>						
	Less: Provision for Current Tax	0.00	0.00	0.00	0.00	0.00	0.00
	Add Provision for Deferred Tax Assets	0.00	0.00	0.00	0.00	0.00	17.50
<b>11</b>	<b>Net Profit / (Loss) for the period</b>	<b>-4.58</b>	<b>-22.62</b>	<b>14.20</b>	<b>-27.20</b>	<b>-4.31</b>	<b>3.78</b>
<b>12</b>	<b>Paid-up equity share capital ( Face Value of Rs. 10/- each)</b>	<b>992.58</b>	<b>992.58</b>	<b>992.58</b>	<b>992.58</b>	<b>992.58</b>	<b>992.58</b>
<b>13</b>	<b>Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
<b>14</b>	<b>Basic and Diluted EPS before &amp; after extraordinary items</b>	<b>-0.05</b>	<b>-0.23</b>	<b>0.14</b>	<b>-0.27</b>	<b>-0.04</b>	<b>0.04</b>

**#Notes**

- (1) The above results were reviewed by Statutory Auditors, recommended by the Audit Committee and approved by the Board of Directors at their respective meeting held on 8th November, 2016.
- (2) The Company is having one segment only and therefore Segmental Reporting is not applicable.
- (3) There are no exceptional/ extraordinary items during the quarter ended 30.09.2016.
- (4) Previous year/period figures have been regrouped/rearranged wherever necessary to make them comparable with current period figures.

Date : 8th November, 2016  
Place : Ankleshwar, Gujarat.

**For, Norris Medicines Ltd.**

  
Vimal D. Shah  
Managing Director



**NORRIS**  
**MEDICINES LIMITED**




**Factory** : Plot No. 801/P, 901/3-5, GIDC Estate,  
ANKLESHWAR 393 002. (Gujarat)  
**Regd. Office** : Plot No. 801/P, GIDC Estate,  
ANKLESHWAR 393 002. (Gujarat)  
**Telephone** : (02646) 223462, 227530  
**Fax** : (02646) 250126  
**E-mail** : contact@norrispharma.com  
**Website** : www.norrispharma.com  
**CIN** : L24230MH1990PLC058071

**New CIN : L24230GJ1990PLC086581**

<b>STATEMENT OF ASSETS AND LIABILITIES</b>	<b>30.09.2016 (Unaudited)</b>	<b>31.03.2016 (Audited)</b>
<b>I. EQUITY AND LIABILITIES</b>		
<b>(1) Shareholder's Funds</b>		
(a) Share Capital	992.57	992.57
(b) Reserves & Surplus	(486.81)	(459.69)
(2) Share Application money pending allotment	-	-
<b>(2) Non - Current Liabilities</b>		
(a) Long Term borrowings	764.41	748.93
(b) Long Term provisions	-	-
<b>(3) Current Liabilities</b>		
(a) Short Term borrowings	57.21	2.31
(b) Trade payables	483.10	253.79
(c) Other current liabilities	36.52	187.02
(d) Short Term provisions	78.52	65.53
<b>TOTAL</b>	<b>1925.52</b>	<b>1790.46</b>
<b>II. ASSETS</b>		
<b>(1) Non -current assets</b>		
(a) Fixed Assets		
(i) Tangible assets	898.05	833.60
(ii) Capital Work in Progress	-	-
(b) Non Current investments	0.88	0.88
(c) Deferred tax assets (net)	139.52	139.52
(d) Long Term Loans and Advances	55.39	137.69
<b>(2) Current Assets</b>		
(a) Current investments	-	-
(b) Inventories	300.52	341.95
(c) Trade Receivables	405.78	277.36
(d) Cash & cash equivalents	27.19	(10.76)
(e) Short Term Loans and advances	98.19	70.22
(f) Other Current assets	-	-
	<b>1,925.52</b>	<b>1,790.46</b>

Date : 8th November, 2016  
Place : Ankleshwar, Gujarat.

**For, Norris Medicines Ltd.**

  
Vimal D. Shah  
Managing Director

**CA. MINU MODI**  
B.Com. F.C.A

**MINU MODI & Co.**  
CHARTERED ACCOUNTANT

232, Rangoli Complex, Station Road,  
Nr. Big Bazar, Bharuch - 392 001.  
☎. (O) (02642) 262260 (R) 244427  
Mobile : 98241 44427, 98241 08141  
E-mail : minumodi70@yahoo.com

LIMITED REVIEW REPORT

To,  
The Board of Directors  
**Norris Medicines Limited**  
Ankleshwar – Gujarat.

We have reviewed the accompanying statement of unaudited financial results of **Norris Medicines Limited** ("the company") for the period ended 30<sup>th</sup> September, 2016. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, *Review of Interim Financial Information Performed by the Independent Auditor of the Entity* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place : BHARUCH  
Date : 8<sup>th</sup> November, 2016

232, Rangoli Complex,  
Station Road,  
Bharuch – 392 001  
Gujarat.



For, **MINU MODI & CO.**  
Chartered Accountants

**CA MINU MODI**  
Proprietor  
M. No. 100289  
(Firm Reg. No. 119948W)